Form 4: Cytokinetics CFO Trades Shares and Options

Cytokinetics EVP, Chief Financial Officer Lee Sung reported transactions involving the acquisition and disposition of common stock and stock options on June 24, 2026.

Summary

• Lee Sung, EVP, Chief Financial Officer of Cytokinetics Inc., engaged in several transactions on June 24, 2026.
• These transactions included the acquisition of common stock at prices ranging from $44.36 to $48.51.
• Additionally, Lee Sung disposed of 38,730 shares of common stock at a price of $82.30 per share.
• The filing also details the acquisition of various stock options, including Non-Qualified Stock Options and Incentive Stock Options, with exercise prices between $44.36 and $48.51.
• These options have varying grant and expiration dates, with some exercisable as early as April 14, 2025, and expiring in 2035.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the acquisition of other shares and options.

Positives

• Acquisition of common stock by a key executive can signal confidence in the company's future prospects.
• The disposal of shares at a higher price ($82.30) than the acquisition prices suggests a profitable transaction for the reporting person.

Negatives

• The disposition of a significant number of shares (38,730) by a high-ranking executive could be interpreted negatively by the market, potentially indicating a lack of confidence or a need for personal liquidity.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. While the acquisition of stock and options by executives can be seen as positive, the sale of a substantial number of shares warrants attention from investors to understand the executive's motivations and potential implications for the stock price.

Stakeholder Impact

• Shareholders may react to the sale of a significant number of shares by the CFO, potentially leading to short-term price fluctuations.
• Employees may interpret the executive's transactions in various ways, influencing morale and perception of company leadership.

Key Dates

Recommendation

The filing reports routine insider transactions. While the sale of shares by the CFO could be a concern, the acquisition of other shares and options, coupled with the lack of other material news, suggests a 'hold' recommendation pending further information or market reaction.

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Stock Options, Beneficial Ownership, SEC Filing, Executive Transactions, Common Stock